• Michael C Snabes, Artur J Jakimiuk, Jan Kotarski, Teresa K Katz, Mark T Brown, and Kenneth M Verburg.
• Pfizer Global Research and Development, Skokie, IL, USA. mcsnabes@comcast.net
• J Clin Anesth. 2007 Sep 1;19(6):448-55.

Study ObjectiveTo assess the analgesic efficacy of a multidose, multiday regimen of intravenous (IV) parecoxib sodium (parecoxib).DesignMulticenter, randomized, double-blind, placebo-controlled, parallel-group trial.SettingPostoperative recovery area and inpatient care facility.Patients422 patients who had undergone gynecologic surgery via laparotomy participated (day 1), and 414 patients were randomized (day 2).InterventionsAfter surgery on day 1, all patients received parecoxib 40 mg (IV), followed by 20 mg (IV) one to 12 hours later; patients were then randomized to receive parecoxib 20 mg (IV) twice daily (n = 211) or placebo (IV) twice daily (n = 203) on days 2 to 5. Patients were permitted rescue medication as needed.MeasurementsPrimary efficacy measures were summed pain intensity through 24 hours (SPI-24) and Patient's Global Evaluation of Study Medication on days 2 and 3.Main ResultsIn the parecoxib treatment group, 24-hour summed pain intensity scores were significantly lower than in the placebo treatment group (P < 0.001) on days 2 and 3. More patients in the parecoxib treatment group rated their treatment as "excellent" or "good" using the Patient's Global Evaluation of Study Medication (P < 0.001) on days 2 and 3. Patients treated with parecoxib had lower pain intensity and consumed less rescue medication compared with the placebo-treated patients.ConclusionMultidose parecoxib was well tolerated over several days and provided improved pain control after gynecologic surgery.

15 keywords...

hide…